Clinical trial
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in…
NCT03222609 · AbbVie, Industry · Completed
Key facts
| NCT number | NCT03222609 |
|---|---|
| Title | A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis |
| Official title | A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Subjects With Myelofibrosis (REFINE) |
| Acronym | REFINE |
| Lead sponsor | AbbVie, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelofibrosis (MF) |
| Intervention type | Drug |
| Interventions | Ruxolitinib, Navitoclax |
| Enrollment | 191 |
| Start date | Oct 31, 2017 |
| Primary completion | Mar 28, 2022 |
| Completion | Jan 29, 2025 |
| First posted | Jul 19, 2017 |
| Last update posted | Jan 20, 2026 |
| Countries | Australia, Canada, Croatia, Greece, Hungary, Israel, Italy, Japan, Puerto Rico, South Korea, Spain, Taiwan and 2 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: